Imiquimod formulation
Solutions of members of the imidazoquinoline family of drugs, such as imiquimod or an analog thereof, are made by combining the drug in a solvent system containing one or more non-aqueous solvents and a hydrogen bond forming compound, wherein the solvent system contains a low level of water.
1 . A solution comprising one or more polar solvents other than water, imiquimod or an analog thereof dissolved within the one or more solvents, and a hydrogen bond forming compound dissolved in the one or more solvents, and optionally water wherein the solution contains 30% w/w or less water.
2 . The solution of claim 1 which is essentially free of water.
3 . The solution of claim 1 which contains water.
4 . The solution of claim 3 wherein the concentration of water contained therein is less than 5 times the concentration of the imiquimod or analog thereof contained in the solution.
5 . The solution of claim 3 wherein the solution contains less than 25% water.
6 . The solution of claim 5 wherein the solution contains less than 20% water.
7 . The solution of claim 6 wherein the solution contains less than 15% water.
8 . The solution of claim 1 which contains a low level of fatty acids that are liquid at room temperature.
9 . The solution of claim 8 which is substantially free of fatty acids that are liquid at room temperature.
10 . The solution of claim 1 wherein the molar ratio of the imiquimod or analog thereof and the hydrogen bond forming compound is between 4:1 and 1:4.
11 . The solution of claim 1 wherein the hydrogen bond forming compound is selected from the group consisting of alpha-hydroxy acids, beta-hydroxy acids, alkyl-sarcosinates, anionic pegylated dimethicone derivatives, anionic oleyl ether surfactants, anionic laureth ether surfactants, cyclic acids, and cyclic acidic sugars.
12 . The solution of claim 1 wherein the solvent is selected from the group consisting of aprotic solvents, cyclic alcohols, short chain liquid alcohols, diols, triols, esters, ethers, pharmaceutical oils, and silicones.
13 . The solution of claim 1 which comprises a polymer having a solubility of at least 0.01% in the one or more solvents.
14 . The solution of claim 13 wherein the polymer is selected from the group consisting of cellulose derivatives, methacrylic acid copolymers, carbomers, pyrrolidone-containing polymers, polyoxyethylene/polyoxypropylene block co-polymers, and polyvinyl alcohols.
15 . The solution of claim 13 wherein the concentration of the polymer in the solution is less than 10% w/w.
16 . The solution of claim 1 which comprises a multiplicity of solvents.
17 . The solution of claim 1 which forms an external or internal phase of an emulsion.
18 . The solution of claim 16 which comprises at least 30% w/w of a volatile solvent.
19 . The solution of claim 20 wherein the volatile solvent is alcohol.
20 . The solution of claim 1 which comprises a polyol.
21 . The solution of claim 20 wherein the polyol is glycerin.
22 . A method for making a solution comprising combining one or more polar solvents other than water and dissolving in the one or more solvents imiquimod or an analog thereof and a hydrogen bond forming compound in an amount sufficient to increase the solubility of the imiquimod or analog in the solution, and optionally combining water in the solution at a concentration of 30% or less w/w of the solution.
23 . The method of claim 22 wherein essentially no water is combined in the solution.
24 . The method of claim 22 wherein water is combined in the solution.
25 . The method of claim 24 wherein the concentration of water that is combined in the solution is less than 5 times the concentration of the imiquimod or analog thereof combined in the solution.
26 . The method of claim 24 wherein water is combined at a concentration of less than 25% w/w of the solution.
27 . The method of claim 26 wherein water is combined at a concentration of less than 20% w/w of the solution.
28 . The method of claim 27 wherein water is combined at a concentration of less than 15% w/w of the solution.
29 . The method of claim 22 wherein fatty acids that are liquid at room temperature are combined in the solution at a concentration of 12.5% w/w or less.
30 . The method of claim 22 wherein substantially no fatty acids that are liquid at room temperature are combined in the solution.
31 . The method of claim 22 wherein the imiquimod or analog thereof and the hydrogen bond forming compound are combined in a molar ration between 4:1 and 1:4.
32 . The method of claim 22 wherein the hydrogen bond forming compound is selected from the group consisting of alpha-hydroxy acids, beta-hydroxy acids, alkyl-sarcosinates, anionic pegylated dimethicone derivatives, anionic oleyl ether surfactants, anionic laureth ether surfactants, cyclic acids, and cyclic acidic sugars.
33 . The method of claim 22 wherein the non-aqueous solvent is selected from the group consisting of aprotic solvents, cyclic alcohols, short chain liquid alcohols, diols, triols, esters, ethers, pharmaceutical oils, and silicones.
34 . The method of claim 22 wherein a polymer having a solubility of at least 0.0 I% is combined in the solution.
35 . The method of claim 34 wherein the polymer is selected from the group consisting of cellulose derivatives, methacrylic acid copolymers, carbomers, pyrrolidone-containing polymers, polyoxyethylene/polyoxypropylene block co-polymers, and polyvinyl alcohols.
36 . The method of claim 34 wherein the concentration of the polymer in the solution is less than 10% w/w.
37 . The method of claim 22 wherein a multiplicity of polar solvents other than water are combined.
38 . The method of claim 37 wherein at least one of the polar solvents other than water is a volatile solvent at a concentration higher than 30%.
39 . The method of claim 38 wherein the volatile solvent is an alcohol.
40 . The method of claim 22 wherein a polyol is combined in the solution.
41 . The method of claim 40 wherein the polyol is glycerin.
42 . A method for increasing the skin penetration of imiquimod or an analog thereof comprising topically administering a pharmaceutical formulation comprising a solution comprising one or more polar solvents other than water, imiquimod or an analog thereof dissolved within the one or more solvents, and a hydrogen bond forming compound dissolved in the one or more solvents, and optionally water wherein the solution contains 30% w/w or less water.
43 . The method of claim 42 wherein the solvent is selected from the group consisting of aprotic solvents, cyclic alcohols, short chain liquid alcohols, diols, triols, esters, ethers, pharmaceutical oils, and silicones.
44 . The method of claim 42 wherein the solution is essentially free of water.
45 . The method of claim 42 wherein the solution contains water.
46 . The method of claim 45 wherein the concentration of water in the solution is less than 5 times the concentration of the imiquimod or analog thereof contained in the solution.
47 . The method of claim 45 wherein the concentration of water in the solution is less than 25%.
48 . The method of claim 47 wherein the concentration of water in the solution is less than 20%.
49 . The method of claim 48 wherein the concentration of water in the solution is less than 15%.
50 . The method of claim 42 wherein the solution contains a low level of fatty acids that are liquid at room temperature.
51 . The method of claim 42 wherein the solution is substantially free of fatty acids that are liquid at room temperature.
52 . The method of claim 42 wherein the molar ratio of the imiquimod or analog thereof and the hydrogen bond forming compound in the solution is between 4:1 and 1:4.
53 . The method of claim 42 wherein the hydrogen bond forming compound is selected from the group consisting of alpha-hydroxy acids, beta-hydroxy acids, alkyl-sarcosinates, anionic pegylated dimethicone derivatives, anionic oleyl ether surfactants, anionic laureth ether surfactants, cyclic acids, and cyclic acidic sugars.
54 . The method of claim 42 wherein the solvent is selected from the group consisting of aprotic solvents, cyclic alcohols, short chain liquid alcohols, diols, triols, esters, ethers, pharmaceutical oils, and silicones.
55 . The method of claim 42 wherein the solution comprises a polymer having a solubility of at least 0.01% in the one or more solvents.
56 . The method of claim 55 wherein the polymer is selected from the group consisting of cellulose derivatives, methacrylic acid copolymers, carbomers, pyrrolidone-containing polymers, polyoxyethylene/polyoxypropylene block co-polymers, and polyvinyl alcohols.
57 . The method of claim 55 wherein the concentration of the polymer in the solution is less than 10% w/w.
58 . The method of claim 42 wherein the solution comprises a multiplicity of solvents other than water.
59 . The method of claim 42 wherein the solution forms an external or internal phase of an emulsion.
60 . The method of claim 58 wherein at least one of the solvents is a volatile solvent at a concentration in the solution of at least 30% w/w.
61 . The method of claim 60 wherein the volatile solvent is an alcohol.
62 . The method of claim 42 wherein the solution comprises a polyol.
63 . The method of claim 62 wherein the polyol is glycerin.